Tags

Type your tag names separated by a space and hit enter

Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Eur J Clin Microbiol Infect Dis. 2020 Jun; 39(6):1021-1026.EJ

Abstract

Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.

Authors+Show Affiliations

Hebei General Hospital, Shijiazhuang, 050051, Hebei, China. lsr64@126.com.Hebei General Hospital, Shijiazhuang, 050051, Hebei, China. Hebei General Hospital, Graduate School of Hebei Medical University, Shijiazhuang, 050000, China.Suzhou University, Suzhou, 215000, Jiangsu, China.The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32285293

Citation

Li, Shu-Ren, et al. "Searching Therapeutic Strategy of New Coronavirus Pneumonia From Angiotensin-converting Enzyme 2: the Target of COVID-19 and SARS-CoV." European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, vol. 39, no. 6, 2020, pp. 1021-1026.
Li SR, Tang ZJ, Li ZH, et al. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. Eur J Clin Microbiol Infect Dis. 2020;39(6):1021-1026.
Li, S. R., Tang, Z. J., Li, Z. H., & Liu, X. (2020). Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 39(6), 1021-1026. https://doi.org/10.1007/s10096-020-03883-y
Li SR, et al. Searching Therapeutic Strategy of New Coronavirus Pneumonia From Angiotensin-converting Enzyme 2: the Target of COVID-19 and SARS-CoV. Eur J Clin Microbiol Infect Dis. 2020;39(6):1021-1026. PubMed PMID: 32285293.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV. AU - Li,Shu-Ren, AU - Tang,Zi-Jian, AU - Li,Zai-Han, AU - Liu,Xuan, Y1 - 2020/04/13/ PY - 2020/03/09/received PY - 2020/03/27/accepted PY - 2020/4/15/pubmed PY - 2020/5/19/medline PY - 2020/4/15/entrez KW - Angiotensin-converting enzyme 2 (ACE2) KW - New coronavirus (COVID-19) KW - SARS coronavirus (SARS-CoV) SP - 1021 EP - 1026 JF - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology JO - Eur J Clin Microbiol Infect Dis VL - 39 IS - 6 N2 - Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development. SN - 1435-4373 UR - https://www.unboundmedicine.com/medline/citation/32285293/Searching_therapeutic_strategy_of_new_coronavirus_pneumonia_from_angiotensin_converting_enzyme_2:_the_target_of_COVID_19_and_SARS_CoV_ L2 - https://dx.doi.org/10.1007/s10096-020-03883-y DB - PRIME DP - Unbound Medicine ER -